Assessment of regulatory T-cell function in forthcoming clinical trials of cell therapy

Expert Review of Molecular Diagnostics

Volumn 13, Issue 1, 2013, Pages 5-7

  Canavan, James B ^a,b   Afzali, Behdad ^a,b   Lord, Graham M ^a,b   Lombardi, Giovanna ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CD154; CD69; CFSE; FOXP3 protein; human; regulatory T cells

Indexed keywords

CYTOKINE;

CELL HETEROGENEITY; CELL PROLIFERATION; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; PATIENT SAFETY; PLASTICITY; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION;

AUTOIMMUNITY; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION IMMUNOLOGY;

EID: 84871586465     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.133     Document Type: Review

References (20)

1. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10(7), 490-500 (2010).
2. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001).
3. Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr. Opin. Organ Transplant. 13(6), 645-653 (2008).
4. Hippen KL, Merkel SC, Schirm DK et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci. Transl. Med. 3(83), 83ra41 (2011).
5. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE 6(1), e15868 (2011).
6. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 90(12), 1321-1327 (2010).
7. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 3(83), 83ra42 (2011).
8. Nadig SN, Wieckiewicz J, Wu DC et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat. Med. 16(7), 809-813 (2010).
9. Trzonkowski P, Bieniaszewska M, Juscinska J et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127? T regulatory cells. Clin. Immunol. 133(1), 22-26 (2009).
10. Brunstein CG, Miller JS, Cao Q et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117(3), 1061-1070 (2011).
11. Di Ianni M, Falzetti F, Carotti A et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117(14), 3921-3928 (2011).
12. Takahashi T, Kuniyasu Y, Toda M et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10(12), 1969-1980 (1998).
13. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188(2), 287-296 (1998).
14. Hasbold J, Gett AV, Rush JS et al. Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester. Immunol. Cell Biol. 77(6), 516-522 (1999).
15. Miyara M, Yoshioka Y, Kitoh A et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6), 899-911 (2009).
16. Canavan JB, Afzali B, Scott?C et al. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 119(8), e57-e66 (2012).
17. Ruitenberg JJ, Boyce C, Hingorani R, Putnam A, Ghanekar SA. Rapid assessment of in vitro expanded human regulatory T cell function. J. Immunol. Methods 372(1-2), 95-106 (2011).
18. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat. Med. 11(10), 1113-1117 (2005).
19. Ukena SN, H?ting M, Velaga S et al. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity. Exp. Hematol. 39(12), 1152-1160 (2011).
20. Afzali B, Mitchell P, Lechler RI, John S, Lombardi G. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin. Exp. Immunol. 159(2), 120-130 (2010).